Trial Profile

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 77-Lu RAD 204 (Primary)
Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Skin cancer; Small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Sponsors Radiopharm Theranostics

Most Recent Events

11 Feb 2026 Planned number of patients changed from 23 to 30.
11 Feb 2026 Planned End Date changed from 1 Oct 2025 to 1 Dec 2027.
11 Feb 2026 Planned primary completion date changed from 1 Jul 2025 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com